GlassScriptPhysician profile
Anoop Appannagari
NPI 1912136979
$120,463.58
in general payments reported to CMS, 2019-2025
44 companies · $37K in 2025
The $37K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $7,132 · 2021: $5,628 · 2022: $9,359 · 2023: $11K · 2024: $40K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Food and Beverage: $8,395 · Travel and Lodging: $3,392 · Consulting Fee: $1,680 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,270.66 |
| Food and Beverage | $8,394.84 |
| Travel and Lodging | $3,392.22 |
| Consulting Fee | $1,680.00 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $37,271.33 | 2022-2025 | Dupixent |
| Genzyme Corporation | $24,354.53 | 2022-2025 | |
| Abbvie INC. | $23,319.61 | 2020-2025 | Linzess, Skyrizi, Rinvoq |
| Allergan, INC. | $14,278.34 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $7,927.19 | 2019-2024 | Linzess |
| Boston Scientific Corporation | $2,272.58 | 2019-2024 | Spyglass, Watchman Flx, Resolution 360 Clip |
| Roche Diagnostics Corporation | $1,680.00 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,531.97 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Nestle Healthcare Nutrition INC. | $1,323.86 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $940.14 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $594.68 | 2019-2025 | Tremfya, Stelara, Remicade |
| Celgene Corporation | $475.33 | 2022-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $388.41 | 2020-2024 | Stelara |
| Pharmacosmos Therapeutics INC. | $378.71 | 2023 | Monoferric |
| Braintree Laboratories, INC. | $367.95 | 2019-2024 | Suflave, Sutab |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $284.71 | 2019-2025 | Visiglide |
| Madrigal Pharmaceuticals | $275.45 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $261.19 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $260.06 | 2022-2025 | Ibsrela |
| Gi Supply, INC. | $240.39 | 2020 | |
| Gilead Sciences, INC. | $220.20 | 2019-2025 | |
| Steris Corporation | $204.13 | 2023 | |
| Ambu INC. | $196.86 | 2020 | |
| Medtronic, INC. | $172.23 | 2022 | |
| Organon LLC | $147.14 | 2023-2025 | Hadlima, Nexplanon |
| Inspire Medical Systems, INC. | $138.64 | 2021 | |
| Ethicon INC. | $137.79 | 2023 | Monarch Platform |
| Merck Sharp & Dohme LLC | $128.56 | 2019-2024 | Dificid |
| Romark Laboratories, Lc | $115.84 | 2019-2020 | |
| Qol Medical, LLC | $107.67 | 2019-2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $62.79 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $51.83 | 2020-2024 | Rebyota |
| Evoke Pharma, INC. | $49.54 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $43.66 | 2020 | |
| Aimmune Therapeutics, INC. | $40.78 | 2024 | |
| Celltrion USA INC. | $38.99 | 2025 | Vegzelma |
| Vivus LLC | $35.04 | 2023-2025 | Pancreaze |
| Lilly USA, LLC | $34.36 | 2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.66 | 2023 | Cyltezo |
| Shionogi INC | $21.08 | 2020 | |
| Daiichi Sankyo INC. | $17.34 | 2022 | |
| Erbe USA INC | $17.00 | 2023 | Erbe Vio |
| Pfizer INC. | $16.97 | 2021 | |
| Novo Nordisk INC | $16.05 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anoop Appannagari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.